|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
ICON Releases Environmental, Social and Governance Report |
 |
|
The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020
Dublin, Ireland, November 22, 2021 — ICON plc (NASDAQ: ICLR) announced today the release of its 2020 Environmental,
Social and Governance (ESG) Report. With the completion of ICON’s
acquisition of PRA Health Sciences, the report presents a unified
overview of the ESG advancements of both legacy organisations during
2020 and sets out the commitments, policies, and outlook for the
combined company.
The ESG Report is available at: https://www.iconplc.com/about/esg/
“As a combined company, new ICON is focused on continuing to develop
its ESG strategy and initiatives,” said ICON CEO Steve Cutler. “This
report may be a look back to 2020, but it also demonstrates the great
promise of the two organisations joining together to become the
healthcare intelligence partner of choice. New ICON will continue to
make a positive social and environmental impact and pursue our ESG goals
and targets.”
For more information about ICON’s ESG efforts, please visit https://www.iconplc.com/about/esg/ |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Generis Appoints Head of Life Sciences as CARA™ Growth Soars
London, UK – January 27th, 2022 - Generis, the creator of CARA™, the
data and content management platform that helps life sciences companies
transform their complex business processes, has created a new Head of
Life Sciences role and appointed Mark Willoughby, a deeply experienced
Regulatory and Quality expert. He will direct both onward platform and
application development and drive new growth for Generis’s CARA™ Life
Science platform.
More info >> |
|
 |
White Papers |
 |
|
Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler
Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >> |
|
|
